These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16446324)

  • 1. First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy.
    Merante S; Chichino G; Boveri E; Gottardi E; Soverini S; Cilloni D; Martinelli G
    J Clin Oncol; 2006 Feb; 24(4):e6-7. PubMed ID: 16446324
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
    Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
    Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
    Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
    Gonçalves A; Monges G; Yang Y; Palmerini F; Dubreuil P; Noguchi T; Jacquemier J; Di Stefano D; Delpero JR; Sobol H; Bertucci F
    J Natl Cancer Inst; 2006 Apr; 98(8):562-3. PubMed ID: 16622127
    [No Abstract]   [Full Text] [Related]  

  • 5. Not all c-kit mutations can be corrected by imatinib.
    Lasota J
    Lab Invest; 2007 Apr; 87(4):317. PubMed ID: 17486696
    [No Abstract]   [Full Text] [Related]  

  • 6. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
    Orzan F; Terreni MR; Longoni M; Boari N; Mortini P; Doglioni C; Riva P
    Oncol Rep; 2007 Jul; 18(1):249-52. PubMed ID: 17549375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
    Tamborini E; Negri T; Miselli F; Lagonigro MS; Pricl S; Pilotti S
    J Natl Cancer Inst; 2006 Nov; 98(21):1583-4. PubMed ID: 17077361
    [No Abstract]   [Full Text] [Related]  

  • 8. Response of histiocytoses to imatinib mesylate: fire to ashes.
    Janku F; Amin HM; Yang D; Garrido-Laguna I; Trent JC; Kurzrock R
    J Clin Oncol; 2010 Nov; 28(31):e633-6. PubMed ID: 20733125
    [No Abstract]   [Full Text] [Related]  

  • 9. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
    Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
    J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
    Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat.
    Nurmio M; Toppari J; Zaman F; Andersson AM; Paranko J; Söder O; Jahnukainen K
    Int J Androl; 2007 Aug; 30(4):366-76; discussion 376. PubMed ID: 17705809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
    Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
    Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM; Bendit I; Epelman S
    Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
    [No Abstract]   [Full Text] [Related]  

  • 15. Imatinib for systemic mast-cell disease.
    Pardanani A; Elliott M; Reeder T; Li CY; Baxter EJ; Cross NC; Tefferi A
    Lancet; 2003 Aug; 362(9383):535-6. PubMed ID: 12932387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
    Rocconi RP; Matthews KS; Kimball KJ; Conner MG; Baker AC; Barnes MN
    Reprod Sci; 2008 Sep; 15(7):673-7. PubMed ID: 18492696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors.
    Ioannou M; Demertzis N; Iakovidou I; Kottakis S
    Anticancer Res; 2007; 27(2):1143-7. PubMed ID: 17465254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis.
    Musto P; Falcone A; Sanpaolo G; Bodenizza C; Carella AM
    Leuk Res; 2004 Apr; 28(4):421-2. PubMed ID: 15109544
    [No Abstract]   [Full Text] [Related]  

  • 19. KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate.
    Mitsuhashi T; Nakayama M; Sakurai S; Fujimura M; Shimizu Y; Ban S; Ogawa F; Hirose T; Ishihara O; Shimizu M
    Ann Diagn Pathol; 2007 Feb; 11(1):49-54. PubMed ID: 17240308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
    Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.